Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis. (17th February 2021)

• Record Type: Journal Article
• Authors: Gómez-Gómez, Alejandro; García-González, Javier; Peiteado, Diana; Borrego-Sanz, Lara; Arriola-Villalobos, Pedro; Esteban-Ortega, Mar; Martín-López, María; Ventura-Hidalgo, María; Perez-Blazquez, Eugenio; Pato, Esperanza; Díaz-Valle, David; Muñoz-Fernández, Santiago; Rodriguez-Rodriguez, Luis
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 2(2021)
• Page Start: 376
• Page End: 387
• Publication Date: 2021-02-17
• Subjects: immunosuppressive drug -- inflammatory relapse -- oral corticosteroids -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1681469
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To estimate the incidence rate (IR) and identify risk factors associated to inflammatory relapse after immunosuppressive drug (ISD) discontinuation in noninfectious uveitis patients. Methods : Multicenter longitudinal retrospective study, including patients from four uveitis clinics followed-up until December 2018. Hazard ratios for different variables were estimated using multivariable Cox models. Results : 32 patients (34 episodes of ISD discontinuation) were analyzed (median and maximum follow-up time: 2.4 and 19.2 years, respectively). Fourteen patients presented at least one relapse: anterior (8 patients), intermediate (5) and posterior (8). IR (95% confidence interval) of the first relapse was 14.3 (8.6–23.8) episodes per 100 patient-years (median survival time: 4.8 years). Early use of ISDs, panuveitis, and higher oral corticosteroid dosage at discontinuation were associated with higher hazards of relapse in multivariable analysis. Conclusions : Relapse is a frequent and early event after ISD discontinuation. Identifying relapse risk factors could support the physician's decision regarding ISD discontinuation.